Trial Profile

A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Daraxonrasib (Primary) ; Elironrasib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Acronyms RMC-LUNG-101B; RMC-LUNG101
Sponsors REVOLUTION Medicines

Most Recent Events

07 Jan 2025 The protocol has been amended.
02 Dec 2024 According to a Revolution Medicines media release, company announced key clinical data updates from this study to be presented during an investor webcast today at 8:00 a.m. Eastern Time (ET).
02 Dec 2024 Results(as data cutoff date an October 28, 2024, n=20)published in the REVOLUTION Medicines Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com